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2445That SCT can be responsible for lethal sudden collapse
(7), including on the athletic ﬁeld, is based on evidence
from the forensic-based US National Sudden Death in
Athletes Registry (4,8,9) and other databases (10), as well
as numerous case reports and considerable expert expe-
rience acquired in athletic venues (5). The epidemiology
and characterization of SCT-related events in athletes are
evolving. A large experience from the US Sudden Death in
Athletes Registry documented SCT-associated collapse
and death in 0.9% of 2462 athletes. This outcome
occurred in 3.3% of the blacks in the registry (4). Ages of
the victims were 12 to 22 years, and 90% were male.
Events were most common in college football players
during conditioning drills.
A distinctive clinical presentation has emerged that
involves gradual deterioration over several minutes.
Symptoms include cramping, dyspnea, muscle pain and
severe weakness, and fatigue and exhaustion, provoked
by vigorous physical exertion, often with sequential
brief bursts of sustained maximal physical activity
(e.g., interval training). Events typically occur early in
the training season or after periods of deconditioning,
often in ambient temperatures $80, at high altitude,
or associated with development of rhabdomyolysis
(4,11–14). Notably, this scenario is in striking contrast
to collapse caused by cardiovascular disease with ven-
tricular tachyarrhythmias, which is typically virtually
instantaneous (8,9).
Although the pathophysiology and clinical deter-
minants of death in people with SCT participating in
intense exercise are not fully understood, cardiovascular
collapse likely occurs under conditions that (in labora-
tory studies) promote HbS polymerization and erythro-
cyte sickling. These include hyperthermia, dehydration,
acidosis, and hypoxemia (11–14). It is possible that with
intense exercise, a cascade of events ensues under un-
predictable circumstances that recreates some of the
laboratory conditions that lead to HbS polymerization
and erythrocyte sickling, thereby triggering vascular oc-
clusion, endothelial damage, and impaired muscular
blood ﬂow (12–16). This exertional sickling scenario
could promote rhabdomyolysis and disseminated intra-
vascular coagulation, which in turn could lead to
hyperkalemia, lactic acidosis, worsening hypoxia, im-
paired cardiac and renal function, and lethal arrhyth-
mias. However, widespread sickling in the heart and
other organs identiﬁed at autopsy does not itself repre-
sent deﬁnitive evidence for SCT-related death, because
postmortem HbS polymerization and erythrocyte sicklingare an expected consequence of the diminished oxygen
environment at death.
These considerations have advanced speciﬁc precau-
tionary recommendations for targeted and tailored mea-
sures during training for athletes with SCT to enhance the
prevention of sudden death (15,16). These precautions,
which can also beneﬁt all athletes, include more gradual
conditioning at the beginning of the training season (or
after periods of deconditioning) with attention to modi-
fying pace, providing adequate rest and hydration during
conditioning drills, and promoting a high index of suspi-
cion to immediately cease physical activity should muscle
weakness, cramping or pain, fatigue, and disproportion-
ately excessive dyspnea occur.
Indeed, collapse of an athlete with SCT is a medical
emergency that requires support of vital signs, adminis-
tration of supplemental oxygen, intravenous hydration,
possibly cooling to protect against fulminating rhabdo-
myolysis, and likely rapid transport to a medical facility.
A metabolic insult with lactic acidosis, hyperkalemia, and
hypocalcemia can lead to pulseless electrical activity, so
that the effectiveness of external deﬁbrillation in this
clinical setting is unpredictable. Such modiﬁed condi-
tioning strategies and surveillance are now widely used
by athletic trainers and coaching staffs in college athletic
programs to prevent SCT-related complications and
catastrophes.
SCT should now be included among the myriad of
nontraumatic risks of sports participation capable of
leading to the demise of some susceptible athletes, the
vast majority of whom are black.
Recommendations
1. Recognition of SCT status is not itself a justiﬁcation
for disqualiﬁcation from competitive sports (Class I;
Level of Evidence C).
2. Recommended preventive strategies (including
adequate rest and hydration) should be performed to
minimize the likelihood of an event occurring on the
athletic ﬁeld in a person known to have SCT (Class I;
Level of Evidence B).
3. It is critical to be prospectively aware of acute emer-
gency medical strategies should suspicion of an
emerging event arise in an athlete known to have SCT
(Class I; Level of Evidence C).
4. Particular caution should be exercised for athletes
known to have SCT who are competing or training in
high environmental temperatures or at extreme alti-
tude (Class I; Level of Evidence C).
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